Učitavanje...
State of the art in CAR T cell therapy for CD19(+) B cell malignancies
Cellular therapy for hematologic malignancies is a rapidly evolving field, with new iterations of novel constructs being developed at a rapid pace. Since the initial reports of chimeric antigen receptor T cell (CAR T cell)success in CD19(+) B cell malignancies, multiple clinical trials of CAR T cell...
Spremljeno u:
| Izdano u: | J Clin Invest |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society for Clinical Investigation
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7108913/ https://ncbi.nlm.nih.gov/pubmed/32235098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI129208 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|